Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Baldwin C, Carette S, Pagnoux C. Linking classification and therapeutic management of vasculitides. Arthritis Res Ther. 2015;17:138.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatol (Oxford). 2009;48(12):1560–1565.
   PubMed Web of Science ®Google Scholar
• Pagnoux C. Churg-Strauss syndrome: evolving concepts. Discov Med. 2010;9(46):243–252.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum. 2013;65(1):270–281.
   PubMed Web of Science ®Google Scholar
• Baldini C, Della Rossa A, Grossi S, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 38 patients from a single Italian centre. Reumatismo. 2009;61(2):118–124.
   PubMedGoogle Scholar
• Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011–1017.
   PubMed Web of Science ®Google Scholar
• Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):686–693.
   PubMed Web of Science ®Google Scholar
• Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–594.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Quemeneur T, Ninet J, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–1127.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cevallos R, Durand-Gasselin B, et al. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris). 1997;148(3):198–204.
   PubMedGoogle Scholar
• Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum. 1992;35(2):208–215.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638–1645.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Tsurikisawa N, Higashi N, et al. Treatment for Churg-Strauss syndrome: induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int. 2007;56(2):97–103.
   PubMedGoogle Scholar
• Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis. 2004;63(12):1649–1654.
   PubMed Web of Science ®Google Scholar
• Crickx E, Machelart I, Lazaro E, et al. Intravenous immunoglobulin as an immunomodulating agent in antineutrophil cytoplasmic antibody-associated vasculitides: a French nationwide study of ninety-two patients. Arthritis Rheumatol. 2016;68(3):702–712.
   PubMed Web of Science ®Google Scholar
• Metzler C, Hellmich B, Gause A, et al. Churg strauss syndrome–successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S52–S61.
   PubMed Web of Science ®Google Scholar
• Metzler C, Schnabel A, Gross WL, et al. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S35–S40.
   Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75(2):396–401.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–69.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Samson M, Puechal X, Devilliers H, et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev. 2014;13(9):945–953.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26–37.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guillevin L. How can patient care be improved beyond medical treatment? Best Pract Res Clin Rheumatol. 2005;19(2):337–344.
   PubMed Web of Science ®Google Scholar
• Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–2935.
   PubMed Web of Science ®Google Scholar
• Durel CA, Berthiller J, Caboni S, et al. Long-term follow-up of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken). 2016;68(3):374–387.
   PubMed Web of Science ®Google Scholar
• Healy B, Bibby S, Steele R, et al. Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome. J Allergy Clin Immunol. 2013;131(2):571–576 e571–576.
   PubMed Web of Science ®Google Scholar
• Kim MY, Sohn KH, Song WJ, et al. Clinical features and prognostic factors of Churg-Strauss syndrome. Korean J Intern Med. 2014;29(1):85–95.
   PubMed Web of Science ®Google Scholar
• Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med. 2003;115(4):284–290.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Wolter NE. Vasculitis of the upper airways. Swiss Med Wkly. 2012;142:w13541.
   Google Scholar
• Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope. 2008;118(2):325–329.
   PubMed Web of Science ®Google Scholar
• McGeoch L, Twilt M, Famorca L, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol. 2016;43(1):97–120.
   PubMed Web of Science ®Google Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–553.
   PubMed Web of Science ®Google Scholar
• Puechal X, Pagnoux C, Baron G, et al. [Abstract 1086] Does adding azathioprine to glucocorticoid induction increase the remission rate and prevent relapses in patients with systemic necrotizing vasculitides without poor-prognosis factors? A multicenter, double-blind randomized controlled trial. Arthritis Rheum. 2015;67:S10.
   Google Scholar
• Cordier JF, Cottin V. Alveolar hemorrhage in vasculitis: primary and secondary. Semin Respir Crit Care Med. 2011;32(3):310–321.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial. 2003;7(2):155–160.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F. Treatment of polyarteritis nodosa and Churg-Strauss syndrome: indications of plasma exchanges. Transfus Sci. 1994;15(4):371–388.
   PubMedGoogle Scholar
• Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation. 2008;117(13):1745–1749.
   PubMed Web of Science ®Google Scholar
• Miszalski-Jamka T, Szczeklik W, Sokolowska B, et al. Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Am Coll Cardiol. 2015;65(1):103–105.
   PubMed Web of Science ®Google Scholar
• Metzler C, Lamprecht P, Hellmich B, et al. Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon {alpha}. Ann Rheum Dis. 2005;64(8):1242–1243.
   PubMed Web of Science ®Google Scholar
• Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006;65(4):557–559.
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2009;60(7):2156–2168.
   PubMed Web of Science ®Google Scholar
• Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133.
   PubMed Web of Science ®Google Scholar
• Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47(7):1104–1105.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26(9):2865–2871.
   PubMed Web of Science ®Google Scholar
• Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65(8):1116–1117.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75(2):396–401.
   PubMed Web of Science ®Google Scholar
• Bouldouyre MA, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68(4):606.
   PubMed Web of Science ®Google Scholar
• Assaf C, Mewis G, Orfanos CE, et al. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol. 2004;150(3):598–600.
   PubMed Web of Science ®Google Scholar
• Lee RU, Stevenson DD. Hydroxyurea in the treatment of Churg-Strauss syndrome. J Allergy Clin Immunol. 2009;124(5):1110–1111.
   PubMed Web of Science ®Google Scholar
• Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, et al. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? Rheumatology (Oxford). 2014;53(2):378–379.
   PubMed Web of Science ®Google Scholar
• Tiliakos A, Shaia S, Hostoffer R, et al. The use of infliximab in a patient with steroid-dependent Churg-Strauss syndrome. J Clin Rheumatol. 2004;10(2):96–97.
   PubMed Web of Science ®Google Scholar
• Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002;206(5):496–501.
   PubMed Web of Science ®Google Scholar
• El-Gamal Y. Churg-Strauss syndrome in the pediatric age group. World Allergy Organ J. 2008;1(2):34–40.
   PubMedGoogle Scholar
• McDermott EM, Powell RJ. Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum Dis. 1998;57(4):258–259.
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63(8):677–682.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708–713.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–116e111.
   PubMed Web of Science ®Google Scholar
• Vennera MC, Picado C, Mullol J, et al. Efficacy of omalizumab in the treatment of nasal polyps. Thorax. 2011;66(9):824–825.
   PubMed Web of Science ®Google Scholar
• Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–324.
   PubMed Web of Science ®Google Scholar
• Graziani A, Quercia O, Girelli F, et al. Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis. Case Report Eur Ann Allergy Clin Immunol. 2014;46(6):226–228.
   PubMedGoogle Scholar
• Wechsler ME, Wong DA, Miller MK, et al. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507–518.
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Kalil J. Omalizumab administration in Churg-Strauss syndrome. Eur J Intern Med. 2009;20(6):e139.
   Google Scholar
• Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol. 2008;121(1):253–254.
   PubMed Web of Science ®Google Scholar
• Puechal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med. 2008;19(5):364–366.
   PubMed Web of Science ®Google Scholar
• Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data from 17 patients. Arthritis Rheumatol. 2016 May. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Agondi R, Kalil J. One year administration of anti-IgE to a patient with Churg-Strauss syndrome. Int Arch Allergy Immunol. 2008;146(2):176.
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, et al. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol. 2008;122(1):217; author reply 217-218.
   PubMed Web of Science ®Google Scholar
• Giavina-Bianchi P, Giavina-Bianchi M, Agondi RC, et al. Anti-IgE in Churg-Strauss syndrome. Thorax. 2009;64(3):272; author reply 272-273.
   PubMed Web of Science ®Google Scholar
• Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax. 2008;63(8):747–748.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215–1228.
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461–467e461–465.
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S62–S65.
   PubMed Web of Science ®Google Scholar
• Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341–343.
   PubMed Web of Science ®Google Scholar
• Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267–270.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA Jr., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29.
   PubMed Web of Science ®Google Scholar
• Cardet JC, Israel E. Update on reslizumab for eosinophilic asthma. Expert Opin Biol Ther. 2015;15(10):1531–1539.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463, 463 e451–453.
   Web of Science ®Google Scholar
• Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol. 2010;22(1):21–28.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol. 2007;19(1):25–32.
   PubMed Web of Science ®Google Scholar
• Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol. 2014;26(1):16–23.
   PubMed Web of Science ®Google Scholar
• Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77(1):82–85.
   PubMed Web of Science ®Google Scholar
• Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612e609.
   PubMed Web of Science ®Google Scholar
• Bain BJ. Review: eosinophils and eosinophilic leukemia. Clin Adv Hematol Oncol. 2010;8(12):901–903.
   PubMedGoogle Scholar
• Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389–413.
   PubMed Web of Science ®Google Scholar
• Horai Y, Miyamura T, Takahama S, et al. Churg-Strauss syndrome associated with elevated levels of serum interleukin-5 and T cell receptor-Cbeta gene rearrangement. Mod Rheumatol. 2011;21(1):76–78.
   PubMed Web of Science ®Google Scholar
• Marmursztejn J, Cohen P, Duboc D, et al. Cardiac magnetic resonance imaging in Churg-Strauss-syndrome. Impact of immunosuppressants on outcome assessed in a prospective study on 8 patients. Clin Exp Rheumatol. 2010;28(1Suppl 57):8–13.
   PubMedGoogle Scholar
• Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford). 2013;52(4):642–650.
   PubMed Web of Science ®Google Scholar
• Dunogue B, Terrier B, Cohen P, et al. Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. Autoimmun Rev. 2015;14(9):774–780.
   PubMed Web of Science ®Google Scholar
• Kostianovsky A, Charles P, Alves JF, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol. 2012;30(1Suppl 70):S83–S89.
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318.
   PubMed Web of Science ®Google Scholar
• Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease–a prospectively controlled vaccination study. Rheumatology (Oxford). 2012;51(4):695–700.
   PubMed Web of Science ®Google Scholar
• Jeffs LS, Peh CA, Jose MD, et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton). 2015;20(5):343–351.
   PubMed Web of Science ®Google Scholar
• Birck R, Kaelsch I, Schnuelle P, et al. ANCA-associated vasculitis following influenza vaccination: causal association or mere coincidence? J Clin Rheumatol. 2009;15(6):289–291.
   PubMed Web of Science ®Google Scholar
• Beretta L, Caronni M, Vanoli M, et al. Churg-Strauss vasculitis with brain involvement following hepatitis B vaccination. Clin Exp Rheumatol. 2001;19(6):757.
   PubMed Web of Science ®Google Scholar
• Groh M, Masciocco G, Kirchner E, et al. Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). J Heart Lung Transplant. 2014;33(8):842–850.
   PubMed Web of Science ®Google Scholar
• Khoury P, Zagallo P, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy. 2012;67(9):1149–1156.
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–1098.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015;70(8):748–756.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692–701.
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330–338.
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. Jama. 2016;315(5):469–479.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466.
   PubMed Web of Science ®Google Scholar